afternoon. this good and for MJ call you for you, Thank our year-end. joining Thank
for First weekend. the lagging. a weather my of And but my over now my all, please little accept is apologies throat the because voice bit under I'm recovering,
make to try point. short and call to this going I'm So the to
opportunity had glance annual hopefully By our have an to now of most you filings. at XXXX
self-reflection results Earlier we to identify numbers a plan what product for. an and this analyze it's understand pathology and need the better quite side in and to hoping we've bit side, XXXX. our sessions team While the shown we in of what not achieve XX% action for time to results growth with do conducting spent the year, approximately on our XX% some obviously on were
with going right XXXX We think releases that believe we're for the the us is reasons have And to the very I'd in some different press shown year be to on of track. XXXX. I you share recent this. a that already like
with Let the begin me business. pathology
the the core As business while But the is we closed majority pathology also makes division. we problem pathology company, of heart the revenue business vision the misdiagnosis. build and product soul of which the vast still to our our the of is of battle XXXX up
meet didn't we However, our goal.
result, significant made a a numbers. within which commercial expect those improvement been changes have the team, we result will of As in
evident evidence number in month. recently in that, history has already a and company's fact, initial record exceeded the of cases of $X in of the we In March million same with finished collections cash
So we going we're track the on forward. right believe
IV-Cell on with engine mind develop lab building need for while building financially such goal rather products. a sustainable, as products, that generating that as the existing to a continue our well we boutique high-class operation pathology samples the order is huge serve team development to for focused in HemeScreen, to and tremendous future division products. customers sales for future Keep patient operation, as we're our the as than is in the Therefore, an of each
financial incentive of our is restructured tiered end the a our team and division. the major around well million. $X addition high on $XX we the of of ended of way that QX for meet the attractively of rate pathology number some cash $XX to for sustainability run breakeven flow about We expect Lab a with million, By a We've breakeven performers. exceed financial to with [ph] XXXX run-rate million. our goal program rewards created customers
force the went task. penetrating product is labs investment. line of is after time year, We to Last direct Precipio fruits HemeScreen with a expensive, through walk the to that simple out and COVID particularly not let's sales we see that Now division. market. our and the takes realized product Building established a
Fortunately, middle were distribution agreement a by approached HemeScreen. XXXX, with pivotal subsequently them find and ThermoFisher of we in the to market
to For sales I doesn't that no that as them those for They equivalent any the world. laboratory don't have Amazon a laboratory ThermoFisher. world of There's of U.S. virtually who from products buy depth reach lab with and indeed of for view in the know the breadth target ThermoFisher HemeScreen. a of is in massive who both the or force expertise, is, access you necessary the successfully the anywhere
session included agreement QX -- work with on officially to by their in launched QX benefits and our the year. formal ongoing with leadership of them training HemeScreen, with team, and we followed market customer ongoing team The educate a launch to in an targeting, last The penetration. them find of by
seen may recognized in New year, award Product this You have for won the of team, that XXXX. HemeScreen January Fisher was for by the Best the and
and are purchase As the a HemeScreen. with significant prospective now result that of in for our we've of us the customers efforts, increase setup engaging pipeline seen
In to virtually customer sales introduce these the combined U.S. a it'll supporting every relationship power but potential addition another distributor, of to force to their and reps base. sales for that be very staff and over healthcare us remains agreement XXX are is which The the actively customer to ThermoFisher forces HemeScreen apartment equals to in unnamed, them, major with in formidable soon with leveraging their
is variable has variable with a commensurate the this This attractive while this that cost growth to and very a model. Precipio makes serves access based force, of commission benefit as [Indiscernible X:XX:XX]. sales is is The structure therefore for cost now a
have to world class grateful that would in the I'm You've to win heard parties, win. it that enough grateful enable that a more that a work scalable, with and that have attractive say before, the for making organizations. I'm force. structure me not competent there's opportunity we And even probably us financially we both is sales build some money world
conversion. If the to is this had word XXXX. for I to to that one describe choose goal Moving word action year,
to deals which that the this the become of revenue with you that signed expected things. recurring financial us customers in up, their two in mind gives and begun customers that we've in Keep releases began our customers, showing press of existing recent some already impact. XQ see You've December
it us ongoing the to an and grow business. in continues First, stream provides revenue we as with come
it financials provides going a and high cash our of with operations, level us predictability needs into manufacturing, forward. Second,
product The the other business customer attractive results. a range showing market sure initial within power indicator seems their our of product I'm financial in. field fact embraced The of very technology. very players operational that a yet to is of for is this the be clinical product adoption economic that of business and is is problem this an The of another solves well registration the us And HemeScreen And aware promising. distributors have real this initial and the attractive laboratory. you're major major
What paint picture roadmaps, thing breakeven. you model The business I'm is our and our more we a virtually nice of the is do our trying shareholder goods. each what as reps, reps revenues, of for no revenues sales hire as our distributors. the We than to is we're about customer that scale up to to HemeScreen leveraging other no there need incremental cost cost sales of means
our simplicity we've very the of are place good to seen news, in is The once help customers require team handle technology. from that the live, most growth. customer part, support is way, it by set they do significant for this little the are that Our us
of annually. well excess our in In production product of $XX are capabilities of currently manufacturing addition, million
the cash foreseeable the a impacts no to this of for So revenue into growth. future, percentage the side for and have attractive significant the model a flow. on where manufacturing support our further the require All can substantial we a bottom investments translates impact the very on company, line,
As reach of operating breakeven. the business now, for for expenses given of projected both pathology million side, the million revenue alongside will at divisions, our our company $X the product $XX
well is achieving that you as goal. on as press our number And releases, as ongoing goal from we reach Our to our well to way see the will that QX year. results, this are
begin our this into happens existing leverage all our on because converted into we where mostly one to are of where focus customers is word, a And revenue taking and introductions the into them conversion. business time Management's structure leaves is entire fixed. This pipeline cash. to our expenses of
channel bottom impact a are margins a for and customer have onboard Our the strong significant distribution has each attractive line. to we we
to So this conversion us blocks of and of revenue recurring into can the expect accounts. of what another see this accelerated this Each year, from for consistent, ongoing pipeline you company. them building is serving as
Lastly, flow I'd discuss and like cash to cash needs.
least ATM as this As in share Any by the as to you announcement know, go our and price. is far our option, very of vehicle been given harmful analysis, facility finance capital a for could prove that would substantial best the the filing process to the diluted periodical using we've is company. our bring the through the have needed. to source In situation capital raise
to simple And continue so we use. inexpensive provides option that ATM the and nice, a will
the raise. the a that believe have down perspective. are earnings the different business grow on are future, to any and to we from focusing point, now, We entirely, once be situation opportunity don't for price to conversion. that positive dramatically. both capital plans one market At grow share changed we'll cap in But and we company, foreseeable action, into hunkering cashflow continue For we then positive any conduct substantial
think have that training a have, XXXX. I didn't to our happy voice the we positioned strong we development with base. QX, our these I marketplace. and have elements I'm commercial year, apologize, the ensuring that the have customer our we partnerships I marketing that way. partners to our team know now with team we sound be building we But you're back didn't upcoming didn't With of we doesn't my is very excited successful have in well have link Last really distribution that today, results. continued product going And in the are our and a from and
Lastly, get that is a our not HemeScreen golden HemeScreen company. despite going promised the the to vision flow on land I focus cash our you that's what's single all us want remind to goose, is screen, of indeed breakeven. to and product to be
going R&D opportunity, for to our team similar scalable to leveraging value continue in products cost HemeScreen on bring have -- these there, low So developed market we've the engine to that and cost. a to But talented low all now, get we similar development. unleash market and to that other we're once bringing market and developing we're products hands
more out. news Thank towards the evening. expect I XXXX. a financial have connecting again and to for items demonstrate that then growth look our company have QX By are we you progress to the you and forward will goals results continued for after nice with our
